Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/64497

metadata.dc.identifier.doi: https://doi.org/10.56042/ijeb.v62i09.5682Title: Investigation of the role of CTLA-4 +49A/G (rs231775) polymorphism in non-small cell lung cancer and T cell immunityAuthors: Isenlik, Burcu Kaya
Yaylim, Ilhan
Dulger, Onur
Kiyan, Hilal Findik
Celik, Faruk Kaan
Hakan, Mehmet Tolgahan
Kucukhuseyin, Ozlem
Kaynak, Kamil
Turna, AkifKeywords: CTLA-4;Lung cancer;NSCLC;T cell immunityIssue Date: Sep-2024Publisher: NIScPR-CSIR,IndiaAbstract: Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) was the first immune checkpoint molecule to be used as a drug target and led the way in the field of immunooncology. CTLA-4 increases the activation threshold of T-cells and reduces immune responses to weak antigens, such as self and tumour antigens. In our study, 56 patients were diagnosed with NSCLC, and a control group of 98 healthy volunteers was included. CTLA-4 +49A/G gene polymorphism and serum CTLA-4 levels were assessed. However, we found that CTLA-4 +49A/G gene polymorphism was associated with lymphovascular invasion (LVI)(P=0.049). The ratio of the heterozygous AG variant was 42.9% in patients with LVI, while it was 14.3% without LVI.This could indicate that the CTLA-4 +49A/G heterozygote AG variant increases the risk of LVI. In addition, we detected withthe CTLA-4 +49A/G heterozygote AG variant had the worst mean overall survival at 56 weeks in the NSCLC patient group(X±SE=56.00±11.52, 95%CI 33.41-78.58, P=0.048). Furthermore, the patient group had significantly higher CTLA-4 serum levels (X±SE=121.57±11.89 pg/mL) compared with the control group (X±SE=79.09±3.09 pg/mL)( P=0.02). Our study dataserve as a guide for future studies to elucidate the pathogenesis of NSCLC and evaluate the therapeutic significance of CTLA-4.Page(s): 713-721ISSN: 0975-1009 (Online); 0019-5189 (Print)Appears in Collections:IJEB Vol.62(09) [September 2024]

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.